Hanx Biopharma Launches AI Drug Development Collaboration With TwinEdge

Hanx Biopharmaceuticals (Wuhan) (HKG:3378) has begun an artificial intelligence-driven drug development collaboration with Switzerland-based TwinEdge Bioscience, according to a Thursday Hong Kong bourse filing. The collaboration will use TwinEdge's artificial intelligence technology and digital twin models to support translational medicine research for Hanx's lead bispecific antibody candidate. Shares of Hanx were up nearly 2% in Friday morning trade.